Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call

PR Newswire February 12, 2015

Xencor to Webcast Presentations at Two Upcoming Conferences in February

PR Newswire February 5, 2015

Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers

PR Newswire January 29, 2015

Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis

PR Newswire January 29, 2015

Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

PR Newswire December 18, 2014

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

PR Newswire December 6, 2014

Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference

PR Newswire December 4, 2014

Xencor to Present at the 2014 Deutsche Bank BioFEST Conference

PR Newswire November 25, 2014

Xencor Reports Third Quarter 2014 Financial Results

PR Newswire November 10, 2014

Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting

PR Newswire November 6, 2014

Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference

PR Newswire November 4, 2014

Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call

PR Newswire November 3, 2014

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease

PR Newswire October 28, 2014

Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel

PR Newswire September 2, 2014

Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference

PR Newswire August 5, 2014

Xencor Reports Second Quarter 2014 Financial Results

PR Newswire July 31, 2014

Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call

PR Newswire July 24, 2014

Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer

PR Newswire July 15, 2014

Xencor Initiates Phase 1 Study of XmAb7195 for Asthma

PR Newswire May 28, 2014

Xencor to Present at Jefferies 2014 Global Healthcare Conference

PR Newswire May 22, 2014